how effective is the rsv vaccine

The RSV vaccines currently available are highly effective, showing about 75% to 83% effectiveness in preventing serious RSV-related outcomes such as hospitalizations and emergency visits in adults aged 60 and older. Both the GSK Arexvy and Pfizer Abrysvo vaccines demonstrated real-world effectiveness in the 77-83% range for preventing RSV hospitalizations and emergency department visits. Moderna's mRNA vaccine, mResvia, showed approximately 80% efficacy in clinical trials. Studies have also indicated durable protection lasting around 18-23 months, though some waning over time is seen. Effectiveness is somewhat lower but still significant among immunocompromised adults. Overall, RSV vaccination substantially reduces severe respiratory illness risk in older adults and those with risk factors, comparable to effectiveness levels seen for flu vaccines.